ImmunoCellular Therapeutics, Ltd. announced the appointment of Gary S. Titus to its board of directors. Mr. Titus is currently the Senior Vice President and Chief Financial Officer of SciClone Pharmaceuticals Inc. and has more than 20 years of business experience in the healthcare and biopharmaceutical industries. Mr. Titus has extensive experience in working with public corporations in a variety of areas, including financial planning and analysis, SEC reporting, investor relations, business development, and corporate strategy.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.199 USD | 0.00% | -0.50% | -14.22% |
1st Jan change | Capi. | |
---|---|---|
-14.22% | 22.54M | |
+50.83% | 56.69B | |
-3.55% | 41B | |
+38.14% | 38.11B | |
-11.22% | 26.89B | |
+14.31% | 25.59B | |
-21.89% | 18.59B | |
-0.25% | 12.39B | |
+26.28% | 11.99B | |
+23.30% | 11.88B |
- Stock Market
- Equities
- IMUC Stock
- News EOM Pharmaceuticals Holdings, Inc.
- ImmunoCellular Therapeutics, Ltd. Appoints Gary S. Titus to Board of Directors